This is a multi-center observational follow-up study to collect saliva samples that allow pharmacogenetic analysis of the subjects that participated in the CC-90007-CP-003 study. Approximately 28 subjects with moderate and severe hepatic impairment and healthy control subjects with normal hepatic function will be enrolled.
Study Type
OBSERVATIONAL
Enrollment
28
Clinical Pharmacology of Miami, LLC
Miami, Florida, United States
Orlando Clinical Research Center OCRC
Orlando, Florida, United States
Volunteer Research Group and New Orleans Center for Clinical Research - Knoxville
Knoxville, Tennessee, United States
Percentage of subjects whose primary saliva sample yields DNA that meets modified PharmacoScan® workflow acceptability criteria
DNA Quality
Time frame: Day 1
Adverse Events (AEs)
Number of participants with adverse event
Time frame: Time from ICF to Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.